Safety of switching from vitamin K antagonists to dabigatran or rivaroxaban in daily care - results from the Dresden NOAC registry

Autor:	Vera Gelbricht, Denise Röllig, Christina Köhler, Eberhard Kuhlisch, Sebastian Werth, Jan Beyer-Westendorf, Franziska Ebertz, Norbert Weiss, Thomas Schreier, Thoralf Stange, Luise Tittl, Ingolf Röder, Christoph Thieme, Kati Förster, Ulrike Hänsel
Rok vydání:	2014
Předmět:	Pharmacology Vitamin medicine.medical_specialty Rivaroxaban business.industry Atrial fibrillation Vitamin k medicine.disease Dabigatran chemistry.chemical_compound chemistry Internal medicine medicine Pharmacology (medical) cardiovascular diseases Intensive care medicine business Previously treated Venous thromboembolism medicine.drug
Zdroj:	British Journal of Clinical Pharmacology. 78:908-917
ISSN:	0306-5251
DOI:	10.1111/bcp.12391
Popis:	Aim Vitamin-K antagonists (VKA) and non-vitamin-K dependent oral anticoagulants (NOAC) have been approved for anticoagulation in venous thromboembolism (VTE) and atrial fibrillation and patients previously treated with VKA are switched to NOAC therapy. Safety data for this switching are urgently needed.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::e72c15fed3e29a163e9a490adae30aca https://doi.org/10.1111/bcp.12391 Zobrazit plný text záznamu Plný text